L. Carnevalli

发表

Dissecting the early steps of MLL induced leukaemogenic transformation using a mouse model of AML

B. Göttgens, D. Adams, Kim Wong, 2020, Nature Communications.

Improved HSC reconstitution and protection from inflammatory stress and chemotherapy in mice lacking granzyme B

E. Laurenti, A. Trumpp, M. Essers, 2014, The Journal of experimental medicine.

Phosphorylation of translation initiation factor eIF2α in the brain during pilocarpine-induced status epilepticus in mice

B. A. Castilho, C. Pereira, B. Longo, 2004, Neuroscience Letters.

A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies

J. Vose, J. Gribben, I. Flinn, 2021, Leukemia & lymphoma.

Tuning mTORC1 activity for balanced self-renewal and differentiation.

A. Trumpp, L. Carnevalli, 2010, Developmental cell.

Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach

A. Lau, D. Jodrell, F. Richards, 2021, EBioMedicine.

A preclinical model of peripheral T‐cell lymphoma GATA3 reveals DNA damage response pathway vulnerability

O. Delpuech, N. Wali, D. Calado, 2022, EMBO molecular medicine.

Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer

Simak Ali, Chun-Fui Lai, A. Harrod, 2022, Oncogene.

Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer

A. McPherson, C. Caldas, M. Jimenez-Linan, 2022, Nature Communications.

Modelling dose and schedule effects of AZD2811 nanoparticles targeting Aurora B kinase for treatment of diffuse large B-cell lymphoma

S. Barry, S. Ashton, J. Pilling, 2019 .

Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response

S. Tavaré, G. Mills, A. McPherson, 2021, Nature Communications.

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer

J. Carroll, O. Delpuech, Rasmus Siersbaek, 2018, Molecular Cancer Therapeutics.

Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer

E. Harrington, Á. Avivar-Valderas, Marcello Maresca, 2018, Oncotarget.

S6K1 plays a critical role in early adipocyte differentiation.

N. Sonenberg, G. Thomas, S. Kozma, 2010, Developmental cell.

Myc Depletion Induces a Pluripotent Dormant State Mimicking Diapause

W. Huber, S. Haas, A. Trumpp, 2016, Cell.

Abstract 100: Novel selective PI3Kγ inhibitor AZD3458 promotes anti-tumor immune responses and reverts resistance to immunotherapy in checkpoint blockade refractory preclinical models

S. Barry, Cristina Gardelli, T. Klinowska, 2019, Tumor Biology.

Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment

S. Barry, H. Ghadially, L. Carnevalli, 2021, Frontiers in Immunology.

Somatic chromosomal number alterations affecting driver genes inform in-vitro and clinical drug response in high-grade serous ovarian cancer

S. Shah, C. Caldas, M. Jimenez-Linan, 2020, bioRxiv.

mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma

S. Thorgeirsson, P. Mischel, B. Aronow, 2012, Science Translational Medicine.

Thomas and Autophagy in Hepatocellular Carcinoma mTOR Inhibitors Synergize on Regression , Reversal of Gene Expression

S. Thorgeirsson, P. Mischel, B. Aronow, 2012 .

Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer

S. Barry, G. Kar, P. Lyne, 2022, Journal for ImmunoTherapy of Cancer.

Metabolic Control by S6 Kinases Depends on Dietary Lipids

P. Pfluger, M. Tschöp, D. Clegg, 2012, PLoS ONE.

Longitudinal tracking of T cell lymphomas in mice using flow cytometry.

C. Sinclair, L. Carnevalli, E. Kuczynski, 2023, STAR protocols.

Phosphorylation of the alpha subunit of translation initiation factor-2 by PKR mediates protein synthesis inhibition in the mouse brain during status epilepticus.

B. A. Castilho, R. Wek, K. Vattem, 2006, The Biochemical journal.

Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity

O. Delpuech, Deanna A. Mele, Molly A. Taylor, 2018, Oncoimmunology.

PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

S. Barry, B. Sidders, K. Hudson, 2018, Journal of Immunotherapy for Cancer.

Translation initiation at non-AUG codons mediated by weakened association of eukaryotic initiation factor (eIF) 2 subunits.

B. A. Castilho, L. Carnevalli, N. N. Hashimoto, 2002, The Biochemical journal.

Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery

S. Barry, Molly A. Taylor, L. Mooney, 2019, Journal of Immunotherapy for Cancer.

Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma

S. Barry, S. Ashton, Shenghua Wen, 2019, Molecular Cancer Therapeutics.

STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1

Mingchao Xie, S. Barry, J. Barrett, 2020, Clinical Cancer Research.

Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition

S. Barry, S. Fawell, A. Ramos-Montoya, 2021, Molecular Cancer Therapeutics.

Abstract 1207: Reversing lactate-driven immunosuppression using the novel, potent and selective MCT4 inhibitor AZD0095

S. Critchlow, G. Hughes, E. Hardaker, 2019, Experimental and Molecular Therapeutics.

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

S. Barry, C. Rooney, J. Urosevic, 2023, NPJ breast cancer.

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment

M. Cobbold, F. Calero-Nieto, Zena Wilson, 2024, Nature communications.

mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma

S. Thorgeirsson, P. Mischel, B. Aronow, 2012, Science Translational Medicine.